KANT Stock Overview

A clinical-stage biotechnology company, engages in developing immunotherapies that transform patients’ lives in the United States. More details

KANT fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months compared to the US market

Has less than 1 year of cash runway

Negative shareholders equity

+ 2 more risks

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Kineta, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Kineta
Historical stock prices
Current Share Price	US$0.25
52 Week High	US$1.15
52 Week Low	US$0.19
Beta	-3.22
1 Month Change	-9.09%
3 Month Change	-50.74%
1 Year Change	-48.02%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-93.33%

Recent updates

Shareholder Returns

	KANT	US Biotechs	US Market
7D	-16.6%	0.8%	1.6%
1Y	-48.0%	-13.8%	11.7%

Return vs Industry: KANT underperformed the US Biotechs industry which returned -14.7% over the past year.

Return vs Market: KANT underperformed the US Market which returned 11.9% over the past year.

Price Volatility

Is KANT's price volatile compared to industry and market?
KANT volatility
KANT Average Weekly Movement	29.3%
Biotechs Industry Average Movement	12.0%
Market Average Movement	8.1%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	4.1%

Stable Share Price: KANT's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: KANT's weekly volatility has increased from 23% to 29% over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	5	n/a	kinetabio.com

Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients’ lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers.

Kineta, Inc. Fundamentals Summary

How do Kineta's earnings and revenue compare to its market cap?
KANT fundamental statistics
Market cap	US$3.43m
Earnings (TTM)	-US$8.57m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.4x

P/E Ratio

Is KANT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KANT income statement (TTM)
Revenue	US$0
Cost of Revenue	US$259.00k
Gross Profit	-US$259.00k
Other Expenses	US$8.31m
Earnings	-US$8.57m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.70
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-13.1%

How did KANT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/19 06:45
End of Day Share Price	2025/05/19 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kineta, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Robert Burns	H.C. Wainwright & Co.
John Vandermosten	Zacks Small-Cap Research

KANT Stock Overview

Risk Analysis

Kineta, Inc. Competitors

Biodexa Pharmaceuticals

Matinas BioPharma Holdings

AquaBounty Technologies

VivoSim Labs

Price History & Performance

Recent News & Updates

Tuhura Biosciences and Kineta Present Updated Results from Kineta's Phase I-Ii Study of Kva12123 and Tuhura's Mechanism of Ifx-Hu2.0 Responses After Anti-Pd-1 Therapy Failure in Advanced Melanoma At the American Association for Cancer Research Annual Meeting

An undisclosed buyer signed an asset purchase agreement to acquire specific intellectual property and related assets of Kineta, Inc for $1.

TuHURA Biosciences, Inc. (NasdaqCM:HURA) entered into a definitive agreement to acquire Kineta, Inc.

Kineta, Inc. Updates KVA12123 Clinical Results from Ongoing Phase 1/2 Vista101 Study at Society for Immunotherapy of Cancer (2024)

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Kineta, Inc. Announces the Extension of the TuHura Biosciences Exclusivity and Right of First Offer Agreement for KVA12123

Recent updates

Tuhura Biosciences and Kineta Present Updated Results from Kineta's Phase I-Ii Study of Kva12123 and Tuhura's Mechanism of Ifx-Hu2.0 Responses After Anti-Pd-1 Therapy Failure in Advanced Melanoma At the American Association for Cancer Research Annual Meeting

An undisclosed buyer signed an asset purchase agreement to acquire specific intellectual property and related assets of Kineta, Inc for $1.

TuHURA Biosciences, Inc. (NasdaqCM:HURA) entered into a definitive agreement to acquire Kineta, Inc.

Kineta, Inc. Updates KVA12123 Clinical Results from Ongoing Phase 1/2 Vista101 Study at Society for Immunotherapy of Cancer (2024)

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Kineta, Inc. Announces the Extension of the TuHura Biosciences Exclusivity and Right of First Offer Agreement for KVA12123

Kineta, Inc.(OTCPK:KANT) dropped from S&P TMI Index

Nasdaq Suspends Trading of Kineta's Common Stock Following Denial of Continued Listing Request, Effective September 19, 2024 and to File Form 25-NSE with the Securities and Exchange Commission

Kineta, Inc.(OTCPK:KANT) dropped from NASDAQ Composite Index

Nasdaq Listing Qualifications Staff Denies Kineta, Inc.'s Request for Continued Listing on the Nasdaq Capital Market

Kineta, Inc. Re Opens Enrollment for the Vista-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

Kineta Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding No Longer Complies with the Requirement Under Nasdaq Listing Rule 5550(b)(1)

High number of new and inexperienced directors

Kineta, Inc., Annual General Meeting, Jun 21, 2024

Kineta Receives Written Notice from Nasdaq Regarding Non-Compliance Minimum Closing Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial

Kineta, Inc. Announces an Update on Its Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating Kva12123

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Announces Restructuring and Workforce Reduction

Kineta, Inc. Announces Update on Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Tumor Activity

Kineta, Inc. Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s 38th Annual Meeting

Kineta, Inc. Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Advanced Solid Tumors

Kineta, Inc. Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 Vista-101 Clinical Trial

New major risk - Share price stability

Kineta Regains Compliance with Nasdaq Listing Rules

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Kineta, Inc. Announces Board Appointments

Third quarter 2022 earnings released

No independent directors